On April 23, 2019, Insys Therapeutics, Inc. (the “Company”) exercised its authority pursuant to Mr. Motahari’s Employment Agreement via power of attorney to tender his resignation as a director of the Company (in connection with his resignation as Chief Executive Officer), effective immediately. Mr. Motahari was also a member of the Board’s Science and Research and Development Committee. On April 17, 2019, the Board appointed Andrew G. Long, effective immediately, to serve as a member of the Board.